Shire plc (NASDAQ:SHPG) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $325 and the lowest price target forecast is $174. The average forecast of all the analysts is $248.92 and the expected standard deviation is $40.26.
Shares of Shire plc appreciated by 2.1% during the last five trading days but lost 3.74% on a 4-week basis. Shire plc is up 5.3% in the last 3-month period. Year-to-Date the stock performance stands at -9.83%. Also, Equity analysts at the Brokerage firm Morgan Stanley assumes its rating on Shire plc (NASDAQ:SHPG). The rating major has initiated the coverage with overweight rating on the shares. The rating by the firm was issued on June 3, 2016.
Shire plc (NASDAQ:SHPG) : Zacks Investment Research ranks Shire plc (NASDAQ:SHPG) as 3, which is a Hold recommendation. 10 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 1.38, which indicates as a Strong Buy.
Shire plc (NASDAQ:SHPG): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $183.86 and $181.52 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $185.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $184.08, notching a gain of 1.89% for the day. The total traded volume was 3,309,758 . The stock had closed at $180.66 on the previous day.
Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).